Jenburkt Pharmaceuticals Sets Key Dates for AGM and Dividend

Jenburkt Pharmaceuticals Ltd. announced its 41st Annual General Meeting (AGM) will be held on September 4, 2026. The company also set August 28, 2026, as the record date for determining shareholder eligibility for any dividend payout.

Key Dates for Shareholders

The 41st Annual General Meeting (AGM) is scheduled for Friday, September 4, 2026. The company has fixed Friday, August 28, 2026, as the record date. This date is crucial for identifying which shareholders are entitled to receive any dividend declared by the company for the financial year ending March 31, 2026. It also serves as the cut-off date for shareholders to be eligible for remote e-voting or to vote during the AGM. Any declared dividend will be disbursed within 30 days following the AGM.

Importance of the AGM and Record Date

Annual General Meetings (AGMs) are fundamental to corporate governance. They offer shareholders a formal platform to engage with management, vote on resolutions, and ask questions. Announcing the AGM date allows shareholders to prepare. The record date is equally important as it clearly defines the cut-off for dividend eligibility, ensuring transparency and fairness for investors who held shares on that specific day.

Company Background

Jenburkt Pharmaceuticals Limited, established in 1985 and headquartered in Mumbai, is an Indian pharmaceutical company. With over three decades of operation, it manufactures and markets pharmaceutical and healthcare products, primarily branded generic formulations for the domestic market. The company also exports to 13 countries. Jenburkt has a history of rewarding shareholders with dividends, with recent annual yields ranging between 1.72% and 3.19%.

What This Means for Shareholders

Shareholders now have specific dates for participation and potential benefits. Those owning Jenburkt Pharmaceuticals shares by August 28, 2026, will be eligible for any dividend declared at the AGM. All shareholders can exercise their voting rights, ensuring their voice is heard in company affairs.

Identified Risks

The announcement is a routine procedural event related to the AGM and dividend declaration. No specific risks or negative events were detailed in the filing concerning this announcement.

Peer Group Overview

Jenburkt Pharmaceuticals operates in the competitive Indian pharmaceutical sector. Major players like Sun Pharmaceutical Industries Ltd., Divis Laboratories Ltd., Torrent Pharmaceuticals Ltd., and Lupin Ltd. also conduct regular AGMs and announce dividends. Jenburkt's focus on branded generics differentiates its market segment within this peer group.

Next Steps for Investors

Investors will await the 41st AGM on September 4, 2026, to see the final decision on dividend declaration and its amount. The subsequent payment of the dividend within 30 days will also be a key event. The company's financial performance for FY2025-26, which underpins the dividend payout, remains critical for investor assessment.